Development and Validation of a Simplified Prognostic Score in SCLC

Area of Science:

• Oncology
• Clinical Prognostics
• Biostatistics

Background:

• Small cell lung cancer (SCLC) patient outcomes vary significantly.
• Accurate prognostic tools are crucial for treatment planning and patient counseling.
• Existing prognostic models may lack simplicity or applicability in routine clinical settings.

Purpose of the Study:

• To develop and validate a Simplified Prognostic Score (SPS) for patients with SCLC.
• To identify key clinical and biological variables that predict overall survival (OS) in SCLC.
• To stratify SCLC patients into distinct prognostic subgroups.

Main Methods:

• Retrospective analysis of 401 SCLC patients treated with etoposide-platinum chemotherapy.
• Development of the SPS using Cox regression model incorporating significant OS determinants.
• Validation of the SPS in an independent cohort of 213 patients from published trials.

Main Results:

• The SPS incorporates TNM stage IV, ECOG performance status >1, liver metastases, and neutrophil-to-lymphocyte ratio >4.
• The score effectively stratified patients into good (26.9 months OS), intermediate (11.5 months OS), and poor (6.8 months OS) prognostic groups.
• Validation cohort confirmed similar stratification with median OS of 27.2, 12.3, and 8.6 months, respectively.

Conclusions:

• The developed SPS is a simple and effective tool for stratifying SCLC patients into three prognostic categories.
• The SPS demonstrates good calibration and discriminative ability in both development and validation cohorts.
• Further validation of the SPS in patients receiving immunochemotherapy is warranted.